Co-administered orally absorbed drugs

Co-administered orally absorbed drugs is a pharmacological designation used to describe the clinical scenario of concomitant medication use rather than a specific molecular target such as a receptor or enzyme (FDA, 2020). This classification is central to the study of drug-drug interactions (DDIs), where the presence of one drug alters the pharmacokinetic or pharmacodynamic profile of another (StatPearls, 2023). Mechanisms of interaction include alterations in gastric pH, chelation, and competition for membrane transporters like P-glycoprotein (P-gp) or metabolic enzymes like Cytochrome P450 3A4 (CYP3A4) in the intestine and liver (NCBI, 2022). These interactions can significantly impact the bioavailability and systemic exposure of orally administered therapeutics, potentially leading to adverse drug reactions or therapeutic failure (PubMed, 2021). Consequently, this category is a primary focus during drug development and regulatory review to establish safe dosing guidelines and identify potential contraindications.

Other names

Concomitant medicationsConcomitant oral drugsDrug-drug interactions (DDIs)Orally administered drugs

Pharmacokinetic interference including enzyme induction or inhibition (e.g., CYP450), transporter competition (e.g., P-gp, OATP), and physicochemical interactions in the gastrointestinal tract such as chelation or pH-dependent solubility changes.